Literature DB >> 376558

Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications.

J E Gadek, S W Hosea, J A Gelfand, M M Frank.   

Abstract

Hereditary angioedema (HAE), an auto-somal dominant disorder characterized by attacks of episodic edema is associated with decreased functional levels of the C1 esterase inhibitor. Approximately 85% of patients have lowered antigen levels of a normal inhibitor protein. 15% of patients have normal or elevated antigenic levels of functionless protein. We have examined the response to danazol therapy of patients with the variant HAE phenotypes possessing the abnormal protein in an effort to determine if these patients possess a normal structural C1 inhibitor allele. Four patients with a variant HAE phenotype were treated successfully with danazol. In two patients, distinguished by the presence of a functionless, albumin-bound, C1 inhibitor (phenotype 2), phenotypic analysis of the danazol response by bidirectional immunoelectrophoresis revealed the appearance of the normal C1 inhibitor gene product during danazol therapy. This relatively cathodal C1 inhibitor peak appears in conjunction with the development of nearly normal functional activity. All of the functional C1 inhibitory activity which appeared in the phenotype 2 treatment serum was associated with the electrophoretically normal inhibitor. This normal protein could be separated from the functionless inhibitor protein by immunoadsorption and molecular sieve chromatography. Danazol therapy of the two patients with an electrophoretically normal, functionless C1 inhibitor (phenotype 3) also resulted in a clinical remission associated with development of a significant increment in functional serum C1 inhibitory activity and C1 inhibitor protein. These findings demonstrate that these two HAE phenotypic variants are heterozygous for the normal serum C1 inhibitor, a finding which was not apparent before phenotypic analysis of this serum during danazol therapy. These data provide strong evidence for a basic similarity between the common form of HAE and its phenotypic variants. They also suggest that a structural gene lesion may result in the abnormalities of serum C1 inhibitor function and disease expression in all three of these HAE phenotypes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 376558      PMCID: PMC372115          DOI: 10.1172/JCI109449

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE.

Authors:  V H DONALDSON; F S ROSEN
Journal:  J Clin Invest       Date:  1964-11       Impact factor: 14.808

2.  A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE.

Authors:  V H DONALDSON; R R EVANS
Journal:  Am J Med       Date:  1963-07       Impact factor: 4.965

3.  HEREDITARY ANGIONEUROTIC EDEMA: TWO GENETIC VARIANTS.

Authors:  F S ROSEN; J PENSKY; V DONALDSON; P CHARACHE
Journal:  Science       Date:  1965-05-14       Impact factor: 47.728

4.  ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS.

Authors:  C B LAURELL
Journal:  Anal Biochem       Date:  1965-02       Impact factor: 3.365

5.  Assay and properties of serum inhibitor of C'l-esterase.

Authors:  L R LEVY; I H LEPOW
Journal:  Proc Soc Exp Biol Med       Date:  1959 Aug-Sep

6.  The cross-linking of proteins with glutaraldehyde and its use for the preparation of immunoadsorbents.

Authors:  S Avrameas; T Ternynck
Journal:  Immunochemistry       Date:  1969-01

Review 7.  Alpha1-antitrypsin and its deficiency.

Authors:  F Kueppers; L F Black
Journal:  Am Rev Respir Dis       Date:  1974-08

8.  Long-term therapy of hereditary angioedema (HAE). Preventive management with fluoxymesterone and oxymetholone in severely affected males and females.

Authors:  P J Davis; F B Davis; P Charache
Journal:  Johns Hopkins Med J       Date:  1974-12

9.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities.

Authors:  J A Gelfand; R J Sherins; D W Alling; M M Frank
Journal:  N Engl J Med       Date:  1976-12-23       Impact factor: 91.245

10.  Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema.

Authors:  F S Rosen; C A Alper; J Pensky; M R Klemperer; V H Donaldson
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

View more
  19 in total

1.  A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency.

Authors:  M M Gompels; R J Lock; J E Morgan; J Osborne; A Brown; P F Virgo
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

Review 2.  Urticaria and angioedema.

Authors:  B A Burrall; A C Huntley
Journal:  Clin Rev Allergy       Date:  1985-02

3.  Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema.

Authors:  M Cugno; J Nuijens; E Hack; A Eerenberg; D Frangi; A Agostoni; M Cicardi
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

4.  Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene.

Authors:  N J Levy; N Ramesh; M Cicardi; R A Harrison; A E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

5.  Purification and characterization of two functionally distinct forms of C1 inhibitor from a patient with angioedema.

Authors:  J G Curd; M Yelvington; R J Ziccardi; D A Mathison; J H Griffin
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

6.  Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon.

Authors:  T Ariga; T Igarashi; N Ramesh; R Parad; M Cicardi; A E Davis
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

7.  Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies.

Authors:  J Alsenz; J D Lambris; K Bork; M Loos
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

8.  Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema.

Authors:  J E Gadek; G A Fells; R L Zimmerman; S I Rennard; R G Crystal
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

9.  Nonsense mutations affect C1 inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema.

Authors:  D Frangi; M Cicardi; A Sica; F Colotta; A Agostoni; A E Davis
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

10.  Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema.

Authors:  J Kramer; Y Katz; F S Rosen; A E Davis; R C Strunk
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.